Skip to main content
Drug bottle and Pill

Compare Olumiant vs. Rinvoq

Head-to-head comparisons of medication uses, side effects, warnings, and more.

Key takeaways

Baricitinib (Olumiant) and upadacitinib (Rinvoq) are both Janus kinase (JAK) inhibitors used to treat rheumatoid arthritis (RA). However, they have different FDA-approved uses and dosing. Baricitinib is also approved for severe hair loss (alopecia areata) and COVID-19 in hospitalized adults needing breathing support, while upadacitinib is used for conditions like ulcerative colitis, eczema, and Crohn's disease, among others. Baricitinib is taken as a 2 mg or 4 mg tablet once daily, depending on the condition, while upadacitinib is typically taken as a 15 mg tablet once daily, with some conditions requiring a higher dose. Upadacitinib is available in both tablet and liquid forms, unlike baricitinib, which is only available as a tablet. Both medications can increase the risk of infections and have potential drug interactions. You should avoid grapefruit juice with upadacitinib due to a potential interaction. Both medications require careful monitoring.

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.